Hemorrhage management system
US-2016270961-A1 · Sep 22, 2016 · US
US11090408B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11090408-B2 |
| Application number | US-201716466073-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 6, 2017 |
| Priority date | Dec 6, 2016 |
| Publication date | Aug 17, 2021 |
| Grant date | Aug 17, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An embodiment includes a system comprising a thermoset polyurethane shape memory polymer (SMP) foam that includes at least one antimicrobial agent. The antimicrobial agent may include at least one phenolic acid that is a pendent group chemically bonded to a polyurethane polymer chain of the SMP foam. Other embodiments are described herein.
Opening claim text (preview).
What is claimed is: 1. A system comprising: a thermoset polyurethane shape memory polymer (SMP) foam that includes at least one antimicrobial agent; wherein the at least one antimicrobial agent includes a phenolic acid, and the SMP foam has a dry glass transition temperature (T g ) above 40 degrees C. and a wet T g below 34 degrees C.; wherein the SMP foam includes a reaction product of hexamethylene diisocyanate (HDI) with one or more of trimethanolamine (TEA), N,N,N′,N′ tetrakis (hydroxyl propylene) ethylenediamine (HPED), or combinations thereof; wherein the phenolic acid is a pendant group chemically bonded, via an ester, to a polyurethane polymer chain of the SMP foam; and wherein the phenolic acid includes one or more of benzoic acid, gentisic acid, 4-hydroxy benzoic acid, p-coumaric acid, vanillic acid, syringic acid, protocatechuic acid, gallic acid, ferulic acid, sinapic acid, caffeic acid, or combinations thereof. 2. The system of claim 1 wherein the SMP foam is physically cross-linked around the at least one antimicrobial agent. 3. The system of claim 1 comprising: a thermoset polyurethane second SMP foam that includes a phenolic acid that is a pendent group chemically bonded to a polyurethane polymer chain of the second SMP foam; and a thermoset polyurethane third SMP foam that includes a phenolic acid that is a pendent group chemically bonded to a polyurethane polymer chain of the third SMP foam; wherein (a) the SMP foam comprises a first foam, and (b) the first, second, and third SMP foams are all enclosed in a sealed kit. 4. The system of claim 1 , wherein the wet T g is below 30 degrees C.
Use of materials characterised by their function or physical properties (liquid bandages A61L26/00) · CPC title
Porous materials, e.g. foams or sponges · CPC title
with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups · CPC title
Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria · CPC title
Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.